domain
gener
abl
neutral
viru
vitro
vivo
use
anim
model
unfortun
point
mutat
identifi
domain
viru
isol
futur
may
recogn
antibodi
mutat
found
domain
indic
region
conserv
domain
may
better
target
antibodi
bind
predict
immunogen
epitop
domain
chemic
synthes
two
peptid
also
express
one
use
recombin
dna
method
screen
phage
display
librari
human
singlechain
antibodi
scfv
predict
epitop
obtain
human
scfv
recogn
sar
viru
vitro
na
novemb
spread
sever
neighbor
area
includ
hong
kong
although
epidem
appear
abat
believ
new
outbreak
sar
possibl
futur
sinc
effect
treatment
current
avail
develop
effect
diagnost
therapeut
control
diseas
paramount
import
last
epidem
sar
patient
show
clinic
improv
given
convalesc
serum
collect
recov
subject
howev
sourc
convalesc
serum
extrem
limit
sera
possibl
transmit
bloodborn
infect
although
anim
use
develop
antiserum
viru
sera
foreign
protein
elicit
immun
respons
may
caus
anaphylact
reaction
thu
would
ideal
develop
human
antibodi
sarscov
prophylaxi
treatment
approach
immun
therapi
clinic
success
appli
malign
diseas
viral
infect
sever
way
develop
human
antibodi
chose
select
antibodi
phage
librari
display
human
singlechain
antibodi
facilit
identif
develop
specif
affin
antibodi
rapid
costeffect
manner
phage
librari
contain
million
independ
clone
singlechain
variabl
fragment
scfv
antibodi
use
select
specif
antibodi
spike
protein
major
antigen
determin
sarscov
order
develop
potent
neutral
highaffin
antibodi
sarscov
spike
protein
respons
receptor
bind
membran
fusion
target
gener
neutral
human
monoclon
antibodi
spike
protein
sarscov
consist
amino
acid
residu
divid
two
subdomain
domain
mediat
bind
viru
receptor
angiotensinconvert
enzym
richli
distribut
surfac
human
lung
cell
domain
mediat
membran
fusion
viru
host
cell
two
strategi
employ
block
infect
sarscov
block
either
bind
domain
receptor
fusion
viru
mediat
domain
sever
human
antibodi
domain
gener
antibodi
neutral
viru
vitro
vivo
howev
point
mutat
identifi
domain
viru
futur
outbreak
may
recogn
antibodi
knowledg
mutat
found
domain
henc
region
conserv
domain
may
better
target
neutral
antibodi
product
use
comput
program
predict
immunogen
domain
peptid
prepar
chemic
synthesi
recombin
protein
express
use
screen
phage
librari
display
human
scfv
antibodi
one
highli
specif
scfv
design
isol
sequenc
express
purifi
show
specif
reactiv
sarscovinfect
vero
cell
vitro
although
neutral
activ
antibodi
undetermin
high
specif
antibodi
sarscov
make
use
diagnosi
sarscov
infect
acid
peptid
design
amino
acid
nfsqilpdplkptkr
acid
peptid
design
amino
acid
llfnkvtladagfmkqygeclgdina
spike
protein
acid
peptid
erlflshpqtktyfphfdlh
design
zeta
irrelev
control
human
globin
protein
synthes
core
facil
univers
california
san
francisco
assess
pure
hplc
peptid
conjug
carrier
protein
bovin
serum
albumin
bsa
pierc
ovalbumin
ova
pierc
describ
manufactur
imject
immunogen
edc
kit
pierc
facilit
pan
amino
acid
sequenc
sarscov
spike
protein
use
design
codonoptim
version
gene
encod
spike
protein
describ
elsewher
oligonucleotid
base
dna
sequenc
encod
amino
acid
llfnkvtladagfmkqygeclgdina
spike
protein
synthes
sequenc
oligonucleotid
aattcgctgttatttaataaggtgaccctggcagacgcgg
gg
tt
synthet
gene
clone
eco
ri
nco
site
bacteri
express
vector
novagen
fuse
thioredoxin
trx
gene
sequenc
confirm
dna
sequenc
ligat
vector
transform
escherichia
coli
novagen
trx
fusion
protein
trx
control
protein
blank
vector
induc
express
isopropylbd
thiogalactopyranosid
iptg
purifi
ninitrilotriacet
acid
ninta
resin
qiagen
accord
manufactur
protocol
scfv
phage
antibodi
librari
construct
fd
phage
fd
phage
display
librari
deriv
phagemid
librari
vector
subclon
sfi
scfv
insert
sfi
site
fd
vector
ligat
mixtur
use
transform
e
coli
transform
mixtur
plate
tye
plate
contain
gml
tetracyclin
librari
size
calcul
count
number
tetracyclineresist
coloni
librari
qualiti
verifi
determin
percentag
clone
insert
appropri
size
scfv
gene
perform
coloni
pcr
screen
use
primer
fdseq
librari
divers
confirm
fingerprint
amplifi
scfv
gene
digest
bst
ni
librari
store
yt
medium
contain
gml
tetracyclin
glycerol
phagedisplay
scfv
specif
synthes
spike
peptid
recombin
peptid
affinityselect
use
protein
absorb
immunotub
nunc
maxisorb
immunotub
coat
gml
bsaconjug
recombin
peptid
overnight
coat
immunotub
block
wv
skim
milk
powder
phosphatebuff
salin
pb
h
room
temperatur
elimin
nonspecif
bind
phage
librari
adsorb
pb
contain
skim
milk
powder
subsequ
plaqueform
unit
phagescfv
prepar
phage
librari
mix
block
buffer
introduc
immunotub
pan
unbound
phage
remov
wash
pb
contain
tween
follow
wash
pb
bound
phage
elut
ml
triethylamin
sigma
neutral
ml
trishcl
ph
use
infect
ml
exponenti
grow
e
coli
e
coli
grown
min
cultur
plate
tye
plate
contain
gml
tetracyclin
overnight
growth
coloni
scrape
plate
use
gener
phage
second
round
select
describ
subsequ
round
pan
select
altern
ovaconjug
bsaconjug
protein
prevent
select
carrier
protein
select
scfv
recombin
peptid
fuse
trx
protein
ml
gml
recombin
trx
control
protein
prepar
blank
vector
without
insert
incub
librari
min
room
temperatur
deplet
phage
elisa
antigenbind
phage
antibodi
identifi
phage
elisa
individu
coloni
pick
microtit
plate
contain
yt
gml
tetracyclin
bacteria
grown
overnight
bacteria
pellet
supernat
contain
phage
particl
use
elisa
spike
protein
fragment
gml
conjug
bsa
ova
recombin
antigen
coat
onto
plate
sodium
bicarbon
solut
ph
overnight
next
day
well
block
h
room
temperatur
skim
milk
powder
pb
l
scfv
phage
supernat
ad
well
incub
h
room
temperatur
plate
wash
phage
bind
detect
antibodi
amersham
pharmacia
describ
manufactur
absorb
read
nm
plate
reader
molecular
devic
spectra
max
number
uniqu
phage
antibodi
estim
pcr
fingerprint
scfv
gene
restrict
enzym
bst
ni
new
england
biolab
confirm
dna
sequenc
sequenc
run
perform
direct
clone
use
primer
primer
scfv
gene
fragment
subclon
psyni
vector
transform
e
coli
novagen
scfv
express
induc
growth
yt
medium
supplement
gml
ampicillin
isopropyld
thiogalactosid
h
scfv
collect
periplasm
solubl
periplasm
extract
obtain
osmot
shock
use
lysi
buffer
contain
sucros
edta
trishcl
ph
scfv
contain
tag
allow
purif
ninta
agaros
column
qiagen
scfv
purifi
periplasm
extract
dialyz
pb
concentr
recombin
protein
prepar
sd
load
buffer
reduc
condit
trishcl
ph
sd
dithiothreitol
glycerol
bromophenol
blue
protein
separ
page
gel
transfer
nitrocellulos
membran
membran
block
nonfat
milk
pb
probe
mous
antihi
tag
antibodi
dilut
overnight
membran
incub
rabbit
antimous
horseradish
peroxidaseconjug
secondari
antibodi
santa
cruz
dilut
h
room
temperatur
reaction
develop
enhanc
chemiluminesc
reagent
pierc
biochip
slide
euroimmun
germani
coat
sarscovinfect
cell
noninfect
cell
util
l
dilut
scfv
sar
patient
serum
ad
well
slide
incub
overnight
slide
wash
pbst
pb
l
dilut
fluoresceinlabel
mous
anticmyc
secondari
antibodi
ad
scfv
well
l
dilut
fluoresceinlabel
goat
antihuman
secondari
antibodi
ad
posit
control
well
slide
incub
room
temperatur
min
slide
wash
pbst
air
dri
mount
mount
slide
observ
fluoresc
microscop
leica
dml
two
domain
spike
protein
cov
domain
carboxyl
end
conserv
subunit
amino
acid
sequenc
spike
protein
analyz
determin
likelihood
sequenc
may
trigger
immun
respons
human
base
predict
antigen
hydrophil
access
secondari
structur
two
epitop
domain
spike
protein
determin
antigen
use
select
singlechain
antibodi
pure
synthet
peptid
conjug
bsa
ova
carrier
protein
increas
coat
effici
immunotub
screen
one
problem
method
may
aris
antibodi
recogn
bsa
ova
carrier
protein
also
select
irrelev
bind
avoid
altern
use
bsaor
ovaconjug
peptid
select
round
phage
scfv
antibodi
select
chemic
synthes
peptid
test
found
hydrophob
insolubl
later
express
fusion
protein
trx
e
coli
solv
solubl
issu
human
nonimmun
phage
display
antibodi
librari
screen
select
scfv
antibodi
specif
predict
antigen
determin
region
spike
protein
round
pan
compris
step
cycl
scfvphage
bind
immobil
antigen
wash
away
unbound
nonspecif
bound
scfvphage
elut
specif
bound
scfvphage
propag
enrich
scfvphage
bacteria
output
phage
scfv
goe
next
round
pan
titer
recov
phage
cfuml
round
select
carrier
proteinconjug
fusion
protein
tabl
increas
number
elut
phage
sever
round
pan
usual
indic
specif
bind
determin
outcom
select
strategi
polyclon
phage
prepar
round
select
analyz
bind
two
target
fragment
elisa
round
pan
output
phage
amplifi
appli
microtit
well
coat
respect
antigen
microtit
well
coat
gml
antigen
bound
phage
detect
horseradish
peroxidas
hrp
conjug
antibodi
phage
elisa
show
enrich
phage
pan
cycl
fig
identifi
phage
specif
bind
antigen
prepar
individu
coloni
round
select
bind
specif
scfv
determin
phage
elisa
use
target
antigen
control
protein
substrat
fortyeight
individu
clone
pick
elisa
analysi
spike
protein
fragment
respect
tabl
random
clone
analyz
clone
specif
recogn
conjug
ova
bsa
protein
control
globin
peptideconjug
ova
protein
ova
bsa
protein
fig
determin
number
uniqu
antibodi
gener
scfv
gene
amplifi
pcr
pcr
product
digest
frequent
cut
restrict
enzym
bst
ni
pcr
fingerprint
scfv
fingerprint
observ
indic
deriv
phage
fig
dna
sequenc
repres
scfv
clone
ident
fig
four
round
select
total
clone
screen
bind
elisa
seventi
clone
specif
recogn
protein
bind
specif
select
phage
antibodi
phage
prepar
individu
coloni
round
select
analyz
specif
bind
elisa
specif
scfv
test
carrier
protein
bsa
ova
carrier
proteinconjug
peptid
singl
clone
obtain
round
pan
test
bind
target
antigen
control
antigen
elisa
bind
phage
detect
hrpconjug
antibodi
signaltonois
ratio
regard
elisa
posit
vector
control
protein
tabl
eight
repres
clone
show
highest
signal
elisa
identifi
fig
clone
subject
dna
fingerprint
analysi
divers
pattern
observ
fig
b
figur
show
dna
sequenc
analysi
clone
highest
specif
affin
bind
four
scfv
higher
bind
activ
tag
vector
express
e
coli
purifi
immobil
metal
affin
chromatographi
reactiv
sarscovinfect
cell
scfv
assess
indirect
immunofluoresc
test
util
biochip
contain
sarscovinfect
cell
noninfect
cell
posit
side
side
reaction
field
immunofluoresc
analysi
reveal
specif
recogn
sarscov
infect
fig
uninfect
vero
cell
fig
b
although
scfv
bound
fusion
protein
elisa
bind
infect
vero
cell
neg
bind
shown
figur
e
scfv
demonstr
show
specif
bind
spike
protein
fragment
peptid
elisa
assay
sarscovinfect
cell
confirm
interact
scfv
recombin
spike
protein
western
blot
perform
figur
found
specif
bind
recombin
protein
vector
control
antihistag
protein
shown
control
sequenc
variat
infecti
virus
limit
develop
effect
vaccin
neutral
antibodi
virus
like
coronaviru
sar
viru
also
use
domain
spike
protein
bind
receptor
host
cell
best
way
block
infect
viru
block
bind
viru
receptor
although
neutral
antibodi
domain
develop
mutat
sar
viru
found
region
henc
viru
may
escap
recognit
neutral
antibodi
howev
domain
well
conserv
among
corona
virus
far
mutat
found
domain
sar
viru
henc
region
better
target
domain
develop
vaccin
neutral
antibodi
sar
viru
furthermor
combin
differ
neutral
antibodi
multipl
epitop
may
facilit
clearanc
viru
human
blood
epitop
fragment
identifi
previous
peptid
strong
bind
convalesc
sera
sar
patient
also
select
potenti
vaccin
sequenc
sar
viru
howev
peptid
hydrophob
hard
dissolv
water
henc
synthes
dna
fragment
peptid
clone
dna
fragment
vector
peptid
express
solubl
fusion
protein
bacteria
purif
recombin
peptid
use
screen
human
scfv
librari
sar
antibodi
obtain
uniqu
clone
recombin
peptid
round
screen
one
clone
specif
bind
activ
sar
viru
perhap
fusion
peptid
chang
conform
fusion
protein
gener
new
epitop
fusion
protein
nevertheless
abl
obtain
one
clone
highli
specif
domain
spike
protein
henc
method
may
use
hydrophob
peptid
target
librari
deplet
blank
recombin
protein
without
peptid
recombin
peptid
need
conjug
carrier
protein
bsa
ova
antihi
scfv
antibodi
may
possibl
therapeut
util
neutral
sarscov
infect
thu
worthwhil
investig
interact
nativ
spike
protein
produc
whole
human
antibodi
viralneutr
assay
provid
precis
assess
neutral
effect
potenti
vivo
clinic
studi
summari
human
scfv
antibodi
direct
spike
protein
sarscov
identifi
bind
specif
sarscov
protein
viral
particl
vh
vl
antibodi
sequenc
thu
facilit
molecular
approach
includ
site
direct
mutagenesi
affin
matur
construct
whole
recombin
human
antibodi
studi
sarscov
neutral
